Study of genetic causes of spinocerebellar ataxia
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study follows people with certain types of spinocerebellar ataxia (a group of conditions that cause progressive movement problems) to understand how the disease changes over time and how genes might influence it. It may help researchers learn more about these conditions and support future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are age 6 or older and have symptoms of ataxia with a genetic diagnosis of one of the listed SCA types (1, 2, 3, 6, 7, 8, 10, 27B, or RFC1) in yourself or a first-degree relative.
- Or are age 18 or older and have a confirmed genetic diagnosis of one of the listed SCA types.
- Or were a participant in the READISCA study and are willing to join again.
- You must be willing and able to give informed consent to participate.
- For the MRI part: must be 18 or older, have a genetic diagnosis of SCA1, 2, or 3, have a low symptom score (SARA < 10), and be able to have an MRI (not pregnant, no other neurological conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with spinocerebellar ataxia type 27B (a movement disorder) and their family members to understand how the condition changes over time. It also includes healthy volunteers for comparison.
This Phase 2 study tests an umbilical cord “stem cell” treatment to improve symptoms in people with spinocerebellar ataxia (a nerve condition that affects balance and walking). It may help walking ability and overall ataxia symptoms, but you must meet specific health and lab safety checks.
This trial tests a non-invasive brain stimulation method called transcranial temporal interference stimulation to see if it can improve symptoms of spinocerebellar ataxia type 3 (a condition affecting balance and coordination). It aims to find the best stimulation settings to help with movement and gait.
This early-phase study tests whether VO659 is safe and how the body processes it in people with certain genetic movement disorders (SCA1, SCA3, or Huntington disease). It may help researchers learn the right dose and whether the drug can be given safely.
This trial studies CADASIL (a genetic blood-vessel condition in the brain) by following people over time with MRI scans, blood draws, and questionnaires. It may help researchers better understand how the condition changes and how factors like medications affect outcomes.
This study is a registry that collects information from adults with certain types of inherited ataxia caused by specific genetic diagnoses. It may help doctors better understand these conditions and support future research.
Hear when a new Spinocerebellar Ataxia Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.